GLP-1 for Sleep Apnea
Zepbound Is the First FDA-Approved Drug for Obstructive Sleep Apnea
In June 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first pharmacological treatment ever approved for OSA. The SURMOUNT-OSA trial showed AHI reductions of up to 63% and full resolution in roughly 30% of patients.
How GLP-1 Medications Treat Sleep Apnea
Obstructive sleep apnea occurs when soft tissue in the throat collapses during sleep, repeatedly blocking the airway. Obesity is the dominant modifiable risk factor — excess fat deposits in the tongue, neck, and pharyngeal walls narrow the airway and make it prone to collapse. This is why weight loss has always been recommended as a treatment for OSA, but achieving sufficient weight loss through diet and exercise alone is notoriously difficult.
GLP-1 receptor agonists — and especially the dual GIP/GLP-1 agonist tirzepatide — produce 18–22% body weight loss in clinical trials, reducing pharyngeal fat deposits enough to substantially widen the airway. The result is dramatic reductions in the apnea-hypopnea index (AHI), the primary measure of sleep apnea severity. Some patients experience complete resolution of OSA; others retain it at a milder, more manageable level.
There may also be direct GLP-1 receptor effects on respiratory drive and upper airway muscle tone, though the weight loss mechanism is believed to be dominant. Ongoing research is exploring whether GLP-1 effects on inflammation and fluid redistribution contribute independently to airway improvement.
The SURMOUNT-OSA Trial: Key Findings
55–63% AHI Reduction
The SURMOUNT-OSA Phase 3 trial enrolled 469 adults with moderate-to-severe OSA and obesity. Over 52 weeks, tirzepatide reduced the apnea-hypopnea index by 55.0 events/hour in participants not using CPAP, and by 62.8 events/hour in CPAP users who discontinued it at study entry. This represents one of the largest AHI reductions ever documented in a clinical trial.
~30% Full OSA Resolution
Roughly 30% of SURMOUNT-OSA participants achieved complete resolution of obstructive sleep apnea — defined as AHI falling below 5 events per hour, the clinical threshold for a normal result. This is an extraordinary outcome for a pharmacological intervention and suggests that GLP-1 therapy may allow many patients to fully eliminate their OSA diagnosis.
Improved Daytime Sleepiness
Beyond the objective AHI measurements, SURMOUNT-OSA participants reported significant improvements in the Epworth Sleepiness Scale score and the PROMIS Sleep Disturbance questionnaire. Patients felt more alert during the day, reported better sleep quality, and experienced improvements in fatigue — outcomes that matter greatly to quality of life.
Cardiovascular Benefits Too
OSA is strongly linked to cardiovascular disease, with each severe apneic event causing oxygen desaturation and sympathetic nervous system activation. SURMOUNT-OSA showed improvements in blood pressure, heart rate variability, and inflammatory markers alongside AHI reduction — suggesting the cardiovascular risk reduction from tirzepatide extends through the OSA treatment pathway.
What This Means for CPAP Users
CPAP (continuous positive airway pressure) therapy remains the gold standard treatment for obstructive sleep apnea. However, CPAP adherence is chronically poor — studies suggest fewer than 50% of patients use their devices consistently. Many patients find the mask uncomfortable, claustrophobic, or disruptive to their sleep and relationships.
GLP-1 therapy offers the possibility of reducing or eliminating CPAP dependence through OSA resolution. In SURMOUNT-OSA, many participants who had previously required CPAP were able to discontinue it during the trial. However, this decision must always be made in consultation with a sleep medicine physician and confirmed with a repeat polysomnography (overnight sleep study).
Patients who continue CPAP while on tirzepatide may notice their required CPAP pressure settings decrease as weight loss reduces airway obstruction. Some CPAP devices with auto-titration (APAP) will adjust automatically; fixed-pressure CPAP may need re-titration at a sleep lab. Always follow up with your sleep specialist every 6–12 months to reassess your therapy needs.
What to Track on GLP-1 Therapy for Sleep Apnea
Frequently Asked Questions
Is Zepbound (tirzepatide) FDA approved for sleep apnea?
Yes. In June 2024, the FDA approved Zepbound (tirzepatide 2.5–15mg, by Eli Lilly) specifically for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first drug ever approved for an OSA indication. The approval was based on the SURMOUNT-OSA Phase 3 trial, which showed reductions in apnea-hypopnea index (AHI) of 55–63% over 52 weeks.
Can I stop using my CPAP if I take Zepbound or Mounjaro?
Possibly, but only after re-evaluation. Approximately 30% of participants in the SURMOUNT-OSA trial achieved complete OSA resolution on tirzepatide. However, CPAP therapy should never be discontinued without a formal repeat sleep study (polysomnography) confirming your AHI has normalized. Discuss any changes to your CPAP therapy with your sleep physician — do not stop independently.
Does Ozempic or Wegovy (semaglutide) also help sleep apnea?
Semaglutide is being actively investigated for obstructive sleep apnea. The SCALE Sleep Apnea trial is evaluating semaglutide 2.4mg (the Wegovy dose) in OSA patients. While awaiting full results, smaller studies and real-world reports suggest meaningful AHI improvements consistent with the degree of weight loss achieved. Only tirzepatide currently has formal FDA approval for OSA.